Abvc Biopharma (ABVC) Other Non-Current Assets (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Other Non-Current Assets came in at $1.8 million in Q1 2026, up 1307.8% YoY from $127128.0 in Q1 2025, and up 158.66% on a QoQ basis from $691900.0 in Q4 2025.
Abvc Biopharma (ABVC) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 15 years of Other Non-Current Assets data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 1307.8% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 1307.8% YoY) and the FY2025 annual result came in at $691900.0, down 38.49% from the prior year.
- Other Non-Current Assets climbed to $1.8 million in Q1 2026, from $691900.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $6.7 million in Q4 2023 to a low of $39977.0 in Q2 2022.
- A 5-year average of $894849.9 and a median of $691900.0 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 3074.34% — and 2024, when it sank 83.23%.
- Tracing ABVC's Other Non-Current Assets over 5 years: stood at $1.3 million in 2022, then jumped by 413.46% to $6.7 million in 2023, then slumped by 83.23% to $1.1 million in 2024, then sank by 38.49% to $691900.0 in 2025, then jumped by 158.66% to $1.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.8 million (Q1 2026), $691900.0 (Q4 2025), and $117017.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 1.79 Mn |
| Dec 31, 2025 | 691,900.00 |
| Sep 30, 2025 | 117,017.00 |
| Jun 30, 2025 | 691,900.00 |
| Mar 31, 2025 | 127,128.00 |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 691,900.00 |
| Jun 30, 2024 | 691,900.00 |
| Mar 31, 2024 | 691,900.00 |
| Dec 31, 2023 | 6.71 Mn |
| Sep 30, 2023 | 44,259.00 |
| Jun 30, 2023 | 213,482.00 |
| Mar 31, 2023 | 63,095.00 |
| Dec 31, 2022 | 1.31 Mn |
| Sep 30, 2022 | 103,218.00 |
| Jun 30, 2022 | 39,977.00 |
| Mar 31, 2022 | 115,664.00 |
| Dec 31, 2021 | 41,157.00 |
| Sep 30, 2021 | 41,099.00 |